COMMENTARY

As Japan’s Contract Drug Rep Ratio Rises, Expectations Grow for Specialist Talent and Flexible Workforce

By Tatsuya Otsuka August 5, 2025

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Japan’s contract drug rep ratio rose to 8.7% in FY2024 as the total number of regular reps continued to fall, the Japan Contract Sales Organization Association (JCSOA) reported in June. Amid industry downsizing, the roles and expectations placed on contract…

To read the full story

Japan’s Contract Rep Ratio Hits Record as Biotechs, Foreign Firms Drive Demand
July 1, 2025

COMMENTARY

Beyond Elevidys: Next-Generation DMD Therapies Advance through Multiple Approaches
March 11, 2026
Elevidys Opens New Era for DMD Treatments Targeting the Underlying Cause
March 10, 2026
ICH Weighs Need for Biosimilar Efficacy Trials as Regulators Move Away from Routine Use
March 9, 2026
G1 Rule to Hit Originator Biologics for First Time, Impact Seen for Up to 13 Brands
February 25, 2026
Hisamitsu’s MBO: Is Shareholder Accountability Trust-Building or a Shackle?
February 18, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Beyond Elevidys: Next-Generation DMD Therapies Advance through Multiple Approaches

By Shinya Sato

The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…